In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

智通财经获悉，美国食品和药物管理局(FDA)周一批准了Hikma仿制诺和诺德(NVO.US)糖尿病药物Victoza，为该药物的另一种仿制药在美国上市扫清了道路。

智通财经获悉，美国食品和药物管理局 (FDA)周一批准了Hikma仿制诺和诺德 (NVO.US)糖尿病药物Victoza，为该药物的另一种仿制药在美国上市扫清了道路。Hikma的品牌仿制药将与Teva制药公司竞争，Teva制药公司今年早些时候在美国推出了Victoza的授权仿制药。

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmac ...

The first generic of the first-generation obesity treatment has been approved in the United States. The U.S. Food and Drug ...